Hengeler Mueller has advised Fresenius SE & Co. KGaA on the strategic realignment (#FutureFresenius) initiated by the new Chief Executive Officer Michael Sen. In this context, Hengeler Mueller is advising on the deconsolidation of the subsidiary Fresenius Medical Care AG & Co. KGaA through a change of legal form into a stock corporation (Aktiengesellschaft).
The Hengeler Mueller team led by partners Thomas B. Paul and Maximilian Schiessl (both Corporate/M&A) includes partners Oliver Rieckers (Corporate, all Dusseldorf), Matthias Scheifele (Tax, Munich), Christian Hoefs (Employment, Frankfurt), Dirk Busch (Capital Markets) and Wolfgang Kellenter (Intellectual Property, both Dusseldorf), counsels Marius Marx (Tax, Frankfurt) and Caspar Haarmann (Capital Markets, Dusseldorf) as well as associates Benedikt Statz (Corporate/M&A), Andreas Tarde (Corporate, both Dusseldorf), Tim Würstlin (Tax, Munich) and Carmen Hartnigk (Corporate, Dusseldorf).
